Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8242337 | 0.74 | ATM (0.43) | TSHR | |
| SCHEMBL7517029 | 0.72 | CYP2C9 (0.41) | ALDH1A1CYP2C9LMNACYP3A4CYP2C19 | |
| SCHEMBL4252207 | 0.72 | CYP2C9 (0.41) | ALDH1A1CYP2C9LMNACYP3A4CYP2C19 | |
| SCHEMBL263371 | 0.71 | ALDH1A1 (0.35) | ALDH1A1CYP2C9LMNACYP3A4CYP2C19 | |
| SCHEMBL17199882 | 0.71 | ALDH1A1 (0.35) | ALDH1A1CYP2C9LMNACYP3A4CYP2C19 | |
| SCHEMBL29043212 | 0.71 | CYP2C9 (0.36) | ALDH1A1CYP2C9LMNACYP3A4CYP2C19 | |
| SCHEMBL4895573 | 0.69 | ALDH1A1 (0.35) | ALDH1A1CYP2C9LMNACYP3A4CYP2C19 | |
| SCHEMBL8593083 | 0.68 | ALDH1A1 (0.34) | ALDH1A1CYP2C9LMNACYP3A4CYP2C19 | |
| SCHEMBL576329 | 0.67 | — | — | |
| SCHEMBL3389445 | 0.67 | ALDH1A1 (0.36) | ALDH1A1CYP2C9LMNACYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0560109-B1 | Process for the preparation of 1-fluorocyclopropyl-methyl-ketone | BAYER AG (DE) | 1996-07-17 | — | — | EP | claimed |
| US-5336809-A | Process for preparing 1-fluorocyclopropyl methyl ketone | BAYER AKTIENGESELLSCHAFT (DE) | 1994-08-09 | — | — | US | claimed |
| EP-0560109-A2 | Process for the preparation of 1-fluorocyclopropyl-methyl-ketone | BAYER AG (DE) | 1993-09-15 | — | — | EP | claimed |
| JP-6009480-A | — | — | None | — | — | JP | disclosed |
| EP-4498449-A2 | FLUORINATED ELECTROLYTE COMPOSITION FOR CHALCOGEN BATTERY | II-VI Delaware, Inc. (US) | 2025-01-29 | — | — | EP | disclosed |
| US-20250006999-A1 | Fluorinated Electrolyte Composition for Chalcogen Battery | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2025-01-02 | — | — | US | disclosed |
| CN-119230953-A | Fluorinated electrolyte composition for chalcogen cells | II-VI特拉华股份有限公司 | 2024-12-31 | — | — | CN | disclosed |
| US-20200054630-A1 | BENZAMIDES-CONTAINING COMPOUNDS AND THEIR USE IN THE TREATMENT OF DEPRESSION | MINDIMMUNE THERAPEUTICS, INC. | 2020-02-20 | — | — | US | disclosed |
| US-10238654-B2 | Benzamides-containing compounds and their use in the treatment of epilepsy | MINDIMMUNE THERAPEUTICS, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-10238654-B2 | Benzamides-containing compounds and their use in the treatment of epilepsy | MINDIMMUNE THERAPEUTICS, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| EP-2906546-B1 | BENZAMIDES | H LUNDBECK AS (DK) | 2018-01-10 | — | — | EP | disclosed |
| US-20140107340-A1 | Benzamides | H. LUNDBECK A/S (DK) | 2014-04-17 | — | — | US | disclosed |
| EP-0560109-B1 | Process for the preparation of 1-fluorocyclopropyl-methyl-ketone | BAYER AG (DE) | 1996-07-17 | — | — | EP | disclosed |
| US-5371295-A | Process for preparing 1-fluorocyclopropyl methyl ketone | BAYER AKTIENGESELLSCHAFT (DE) | 1994-12-06 | — | — | US | disclosed |
| US-5371295-A | Process for preparing 1-fluorocyclopropyl methyl ketone | BAYER AKTIENGESELLSCHAFT (DE) | 1994-12-06 | — | — | US | disclosed |
| US-5336809-A | Process for preparing 1-fluorocyclopropyl methyl ketone | BAYER AKTIENGESELLSCHAFT (DE) | 1994-08-09 | — | — | US | disclosed |
| US-5336809-A | Process for preparing 1-fluorocyclopropyl methyl ketone | BAYER AKTIENGESELLSCHAFT (DE) | 1994-08-09 | — | — | US | disclosed |
| JP-H069480-A | PREPARATION OF 1-FLUOROCYCLOPROPYL METHYL KETONE | BAYER AG | 1994-01-18 | — | — | JP | disclosed |
| EP-0560109-A2 | Process for the preparation of 1-fluorocyclopropyl-methyl-ketone | BAYER AG (DE) | 1993-09-15 | — | — | EP | disclosed |
| EP-0560109-A2 | Process for the preparation of 1-fluorocyclopropyl-methyl-ketone | BAYER AG (DE) | 1993-09-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200054630-A1 | BENZAMIDES-CONTAINING COMPOUNDS AND THEIR USE IN THE TREATMENT OF DEPRESSION | P2RX5, P2RX7, P2RX2 | ALDH1A1 637/4885CYP2C9 713/4885LMNA 1650/4885 |
| US-20140107340-A1 | Benzamides | P2RX7, TRPV1, P2RX5 | ALDH1A1 1424/4885CYP2C9 1236/4885LMNA 2027/4885 |
| US-10238654-B2 | Benzamides-containing compounds and their use in the treatment of epilepsy | P2RX5, P2RX7, P2RX6 | ALDH1A1 767/4885CYP2C9 306/4885LMNA 1674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.